Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-148-4
CAS number: 25637-99-4
The following information is available for neurotoxicity potential of the registered substance:Mariussen, E. and Fonnum, F. (2003). The effect of brominated flame retardants on neurotransmitter uptake into rat brain synaptosomes and vesicles. Neurochemistry International (2003), Vol. 43, pp.533-542.Reistad, T., Fonnum, F. and Mariussen, E. (2006). Neurotoxicity of the pentabrominated diphenyl ether mixture, DE-71, and hexabromocyclododecane (HBCD) in rat cerebellar granule cells in vitro. Arch. Toxicol. (2006), Vol. 80, pp.785-795.It was not possible to score either neurotoxicity studies for reliability due to non-standard methodologies and lack of reporting of scientific principles. The studies were therefore both awarded reliability scores of 4 according to the criteria of Klimisch et al. (1997). It should be noted that the concentrations used in those assays are far above the water solubility of HBCDD and probably yhe solubility in the media. In vitro studies under those conditions are of questionable value and no conclusion can be drawn from those experiments.
Mariussen et al. (2003) conducted several experiments to evaluate the
effect of brominated flame retardants, including the registered
substance, on neurotransmitter uptake in rat brain synaptosomes and
vesicles. Original test methodologies were used to model the effect of
the registered substance on the rat brain, which makes comparing the
investigations carried out by Mariussen et al. (2003) to other
investigations difficult. Mariussen et al. (2003) reported that the
registered substance inhibited the uptake of dopamine (IC50 4±1µm) and
Glutamate (IC50 26±9µm) in rat synaptosomes and partly inhibited TPP+
uptake in rat synaptosomes under the conditions of the test. Mariussen
et al. (2003) also reported that the registered substance induced the
death of CGC in low micromolar concentrations.
Reistad et al. (2006) also examined the effect of the registered
substance on vesicular uptake of dopamine in the rat brain, however, the
methodology differed significantly from that employed by Mariussen et
al. (2003). Reistad et al. (2006) concluded that the registered
substance inhibited dopamine uptake in the rat brain and reported an
IC50 value of 3±1µm.
No classification for neurotoxicity or adverse effect upon the central
nervous system has been placed upon the registered substance. The
available data do not indicate any specific target organ toxicity at
relevant dose levels. In vitro data are not of a quality that they can
be used in an assessment of the human health effects of the substance.
They are also of limited use for considerations on a mode of action.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Questo sito web si avvale di cookie affinché possiate usufruire della migliore esperienza sui nostri siti web.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again